<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929666</url>
  </required_header>
  <id_info>
    <org_study_id>ZWI-ZW25-201</org_study_id>
    <nct_id>NCT03929666</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer</brief_title>
  <official_title>Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zymeworks Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zymeworks Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate&#xD;
      the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard&#xD;
      first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers.&#xD;
      Eligible patients include those with unresectable, locally advanced, recurrent or metastatic&#xD;
      HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or&#xD;
      colorectal cancer (CRC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard&#xD;
      first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without&#xD;
      bevacizumab for CRC; and CisGem for BTC) and will confirm the recommended dosage (RD) of ZW25&#xD;
      when administered in combination with each of these multi-agent chemotherapy regimens. Then,&#xD;
      Part 2 of the study will evaluate the anti-tumor activity of ZW25 plus combination&#xD;
      chemotherapy in HER2-expressing GEA, BTC, and CRC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs) (Part 1)</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Number of participants who experienced a DLT. DLTs include adverse events considered to be related to study treatment, including the evaluated dose level of ZW25, any component or combination of the components of a chemotherapy regimen, or the combination of ZW25 plus a chemotherapy regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (Part 1)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Number of participants who experienced an adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of lab abnormalities (Part 1)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology and chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) (Part 2)</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Number of participants who achieved a best response of either complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) (Part 1)</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Number of participants who achieved a best response of either CR or PR during treatment per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (Parts 1 and 2)</measure>
    <time_frame>Up to 10 months</time_frame>
    <description>Number of participants who achieved a best response of CR, PR, or stable disease (SD) during treatment per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (Parts 1 and 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median duration of response (in months) and range (minimum, maximum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (Parts 1 and 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants with SD for â‰¥ 24 weeks or a confirmed, best overall response of CR or PR per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (Parts 1 and 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median progression-free survival (in months) and range (minimum, maximum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Parts 1 and 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Median overall survival (in months) and range (minimum, maximum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs) (Parts 1 and 2)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Number of participants who develop ADAs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of infusion concentration of ZW25 (Parts 1 and 2)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration of ZW25 (Parts 1 and 2)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration of ZW25 (Parts 1 and 2)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (Part 2)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Number of participants who experienced an adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of lab abnormalities (Part 2)</measure>
    <time_frame>Up to 11 months</time_frame>
    <description>Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology and chemistry. Grades are defined using National Cancer Institute's CTCAE, version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">362</enrollment>
  <condition>HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>ZW25 + FP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZW25 plus fluorouracil (5-FU) and cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZW25 + mFOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZW25 plus 5-FU, leucovorin, and oxaliplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZW25 + XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZW25 plus capecitabine and oxaliplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZW25 + mFOLFOX6 with bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZW25 plus 5-FU, leucovorin, oxaliplatin, and bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZW25 + CisGem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZW25 plus cisplatin and gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZW25 (Zanidatamab)</intervention_name>
    <description>Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)&#xD;
Part 2: RD identified in Part 1</description>
    <arm_group_label>ZW25 + FP</arm_group_label>
    <arm_group_label>ZW25 + XELOX</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6 with bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Administered orally twice daily (PO bid)</description>
    <arm_group_label>ZW25 + XELOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ZW25 + CisGem</arm_group_label>
    <arm_group_label>ZW25 + FP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ZW25 + FP</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6 with bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ZW25 + mFOLFOX6</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6 with bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ZW25 + XELOX</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6</arm_group_label>
    <arm_group_label>ZW25 + mFOLFOX6 with bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ZW25 + mFOLFOX6 with bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>ZW25 + CisGem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Disease diagnosis:&#xD;
&#xD;
               -  Part 1:&#xD;
&#xD;
               -  GEA: Unresectable, locally advanced, recurrent or metastatic HER2-expressing GEA&#xD;
                  (IHC 3+ or 2+ with or without gene amplification based upon local assessment or&#xD;
                  central assessment)&#xD;
&#xD;
               -  BTC: Unresectable, locally advanced, recurrent or metastatic HER2-expressing BTC&#xD;
                  (including intrahepatic cholangiocarcinoma [ICC], extrahepatic cholangiocarcinoma&#xD;
                  [ECC], or gallbladder cancer [GBC]) (IHC 3+ with or without gene amplification;&#xD;
                  or IHC 0, 1+ or 2+ with gene amplification, based upon central assessment)&#xD;
&#xD;
               -  CRC: Unresectable, locally advanced, recurrent or metastatic HER2-expressing CRC&#xD;
                  (IHC 3+ with or without gene amplification; or IHC 0, 1+ or 2+ with gene&#xD;
                  amplification, based upon central assessment). Patients will be required to be&#xD;
                  extended RAS (KRAS and NRAS) and BRAF wild-type based upon central assessment.&#xD;
&#xD;
               -  Part 2:&#xD;
&#xD;
               -  GEA: Unresectable, locally advanced, recurrent or metastatic HER2-expressing GEA&#xD;
                  (IHC 3+, or IHC 2+ and FISH+ by central assessment)&#xD;
&#xD;
               -  BTC: Same as Part 1&#xD;
&#xD;
               -  CRC: Same as Part 1&#xD;
&#xD;
          -  Tumor measurements as per Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             version 1.1:&#xD;
&#xD;
               -  Part 1: Measurable or non-measurable disease&#xD;
&#xD;
               -  Part 2: Measurable disease&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Adequate cardiac left ventricular function, as defined by a LVEF &gt;/= institutional&#xD;
             standard of normal&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Prior treatment with a HER2-targeted agent&#xD;
&#xD;
          -  Prior systemic anti-cancer therapy (including investigational products) except prior&#xD;
             adjuvant/neoadjuvant therapy, which must be completed at least 6 months prior to first&#xD;
             study treatment dosing. For subjects with BTC and CRC the following additional&#xD;
             exceptions apply:&#xD;
&#xD;
               -  BTC: patients may have started therapy for advanced disease but may not have&#xD;
                  received more than one cycle of any standard gemcitabine-based chemotherapy&#xD;
                  regimen.&#xD;
&#xD;
               -  CRC: patients may have started therapy for advanced disease but may not have&#xD;
                  received more than one cycle of 5-FU-based chemotherapy (&lt; 1 month of therapy).&#xD;
&#xD;
          -  Patients with certain contraindications to bevacizumab cannot be enrolled on the&#xD;
             mFOLFOX6-2 with bevacizumab arm.&#xD;
&#xD;
          -  Palliative radiotherapy is allowed if completed at least 2 weeks prior to first study&#xD;
             treatment dosing&#xD;
&#xD;
          -  Untreated known brain metastases (patients with treated brain metastases who are off&#xD;
             steroids, off antiseizure medications, and stable for at least 1 month at the time of&#xD;
             screening are eligible)&#xD;
&#xD;
          -  Clinically significant cardiac disease, such as ventricular arrhythmia requiring&#xD;
             therapy, uncontrolled hypertension or any history of symptomatic congestive heart&#xD;
             failure (CHF). Patients with known myocardial infarction or unstable angina within 6&#xD;
             months prior to randomization are also excluded.&#xD;
&#xD;
          -  QTc Fridericia (QTcF) &gt; 470 ms. For patients with longer QTcF on initial&#xD;
             electrocardiogram (ECG), follow-up ECG may be performed in triplicate to determine&#xD;
             eligibility&#xD;
&#xD;
          -  Peripheral neuropathy &gt; Grade 1 per NCI-CTCAE v5.0&#xD;
&#xD;
          -  Clinically significant interstitial lung disease&#xD;
&#xD;
          -  Prior or concurrent malignancy whose natural history or treatment has the potential to&#xD;
             interfere with the safety or efficacy assessment of the investigational regimen&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection or infection with Human Immunodeficiency&#xD;
             Virus (HIV)-1 or HIV-2 (Exception: patients with well controlled HIV [e.g., CD4 &gt;&#xD;
             350/mm3 and undetectable viral load] are eligible)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Grim, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Zymeworks Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zymeworks Clinical Trial Resource</last_name>
    <phone>(206) 237-1030</phone>
    <email>medinfo@zymeworks.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Syma Iqbal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rutika Mehta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer and Hematology Centers of Western Michigan</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sreenivasa Chandana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joel Michalski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geoffrey Ku, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Namrata Vijayvergia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaffer Ajani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruce Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Elimova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Keun-Wook Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Young Mi Seol, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yeul Hong Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Do-Youn Oh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sun Young Rha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>Bispecific antibody</keyword>
  <keyword>Biparatopic antibody</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Gastric cancers</keyword>
  <keyword>Esophageal cancers</keyword>
  <keyword>Gastroesophageal junction (GEJ) cancers</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>FP</keyword>
  <keyword>mFOLFOX6</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>5-FU</keyword>
  <keyword>Leucovorin (folinic acid)</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>XELOX</keyword>
  <keyword>Gastrointestinal cancers</keyword>
  <keyword>Gastroesophageal adenocarcinoma</keyword>
  <keyword>Biliary tract cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Intrahepatic cholangiocarcinoma</keyword>
  <keyword>Extrahepatic cholangiocarcinoma</keyword>
  <keyword>Gall bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

